Acalabrutinib Plus Bendamustine and Rituximab in Untreated MCL: Results From the Phase 3 ECHO Trial

Key opinion leaders examine the current frontline treatment options for mantle cell lymphoma while identifying critical unmet patient needs requiring attention.

The panelists evaluate the preliminary efficacy findings from the ECHO trial and address how the COVID-19 pandemic influenced overall survival outcomes in the study.

Medical experts analyze and provide insights on safety findings from the Phase 3 ECHO trial, offering their professional interpretations of the data.

Medical experts evaluate unmet needs, key insights from the Phase 3 ECHO trial, and potential obstacles in integrating the findings into existing treatment protocols.

Brad S. Kahl, MD, and Tycel Phillips, MD, discussed the use of acalabrutinib plus bendamustine and rituximab for patients with untreated MCL.